https://www.pharmaradar360.com/article/nipah-virus-disease-india-4ba4a82cc627e48dPharma Surgeen2026-06-25T18:00:00.000ZNipah virus disease - Indiahttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-06-25T16:23:37.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/drug-to-prevent-organ-rejection-after-kidney-transplant-tops-standard-treatment-4add60b421db13b6Pharma Surgeen2026-06-25T16:11:35.000ZDrug to prevent organ rejection after kidney transplant tops standard treatment in trialhttps://www.pharmaradar360.com/article/fda-will-reportedly-conclude-abortion-pill-safety-review-by-september-343203b30dba9d6dPharma Surgeen2026-06-25T16:06:00.000ZFDA Will Reportedly Conclude Abortion Pill Safety Review by Septemberhttps://www.pharmaradar360.com/article/senate-unanimously-passes-boscola-backed-legislation-to-modernize-pharmaceutical-66ce988cc92e19cePharma Surgeen2026-06-25T15:41:09.000ZSenate Unanimously Passes Boscola-Backed Legislation to Modernize Pharmaceutical Licensinghttps://www.pharmaradar360.com/article/therapeutics-stocks-q1-teardown-biomarin-pharmaceutical-nasdaq-bmrn-vs-the-rest-56344bfd686cf92dPharma Surgeen2026-06-25T15:37:50.000ZTherapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Resthttps://www.pharmaradar360.com/article/tianjin-development-says-lisheng-pharmaceutical-subscribes-to-investment-product-5908f523f0d969d3Pharma Surgeen2026-06-25T15:33:51.000ZTianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Millionhttps://www.pharmaradar360.com/article/biotech-etf-index-surges-10-after-rebalance-1edcbf3595d1bd45Pharma Surgeen2026-06-25T15:32:51.000ZBiotech ETF Index Surges 10% After Rebalancehttps://www.pharmaradar360.com/article/krystal-biotech-stock-hits-all-time-high-at-357-65-usd-4abb039116198537Pharma Surgeen2026-06-25T15:31:18.000ZKrystal Biotech stock hits all-time high at 357.65 USDhttps://www.pharmaradar360.com/article/2546-a-cluster-randomised-controlled-trial-of-air-filtration-to-prevent-symptoma-5984674e16dbc3d5Pharma Surgeen2026-06-25T15:19:35.000Z2546: A cluster randomised controlled trial of Air Filtration to prevent symptomatic winter Respiratory Infections (including COVID-19) in care homes (AFRI-c)https://www.pharmaradar360.com/article/scoop-members-of-congress-told-abortion-pill-safety-review-possible-by-september-4e04bb31595eb57fPharma Surgeen2026-06-25T15:11:08.000ZSCOOP: Members of Congress Told Abortion Pill Safety Review Possible by Septemberhttps://www.pharmaradar360.com/article/3-fragen-an-unser-neues-boardmitglied-michele-ravara-general-manager-abbvie-swit-23ac6f5425b37523Pharma Surgeen2026-06-25T15:10:21.000Z3 Fragen an unser neues Boardmitglied: Michele Ravara, General Manager AbbVie Switzerlandhttps://www.pharmaradar360.com/article/geodis-tests-sustainable-paper-thermal-covers-for-pharmaceutical-airfreight-3801ee1b6af6c9bdPharma Surgeen2026-06-25T15:09:54.000ZGEODIS tests sustainable paper thermal covers for pharmaceutical airfreighthttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-may-2026-b766133bf277f757Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: workforce management information May 2026https://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-january-to-marc-2fa50abc78b19ba4Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: senior officials’ business expenses, hospitality and meetings, January to March 2026https://www.pharmaradar360.com/article/dhsc-ministerial-travel-and-meetings-january-to-march-2026-39ee0c30f2ed7e92Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: ministerial travel and meetings, January to March 2026https://www.pharmaradar360.com/article/dhsc-ministerial-gifts-hospitality-overseas-travel-and-meetings-2332d5d2f3822f2ePharma Surgeen2026-06-25T15:00:08.000ZDHSC: ministerial gifts, hospitality, overseas travel and meetingshttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: workforce management informationhttps://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-a328912eb87631b3Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: senior officials’ business expenses, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-52d34624ad3609c5Pharma Surgeen2026-06-25T15:00:05.000ZDHSC: special advisers' gifts, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-january-to-march-2026-f054ee78b3c87d08Pharma Surgeen2026-06-25T15:00:04.000ZDHSC: special advisers' gifts, hospitality and meetings, January to March 2026https://www.pharmaradar360.com/article/overwhelmingly-a-positive-development-fda-finally-stops-blocking-safe-effective-ca5e9a64365c276aPharma Surgeen2026-06-25T14:46:57.000Z"Overwhelmingly a Positive Development": FDA Finally Stops Blocking Safe, Effective Bemotrizinol Sunscreenshttps://www.pharmaradar360.com/article/contact-the-department-of-health-and-social-care-dhsc-e9faf95887d9a23dPharma Surgeen2026-06-25T14:41:34.000ZContact the Department of Health and Social Care (DHSC)https://www.pharmaradar360.com/article/complaints-procedure-77a8386b7ea0797aPharma Surgeen2026-06-25T14:40:46.000ZComplaints procedurehttps://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3Pharma Surgeen2026-06-25T14:30:00.000ZHealth Protection Report volume 20 (2026)https://www.pharmaradar360.com/article/the-china-debate-gets-louder-in-washington-09b5ff424f78e3e1Pharma Surgeen2026-06-25T14:25:18.000ZThe China debate gets louder in Washingtonhttps://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60Pharma Surgeen2026-06-25T14:00:00.000ZMeningococcal disease: laboratory-confirmed cases in England 2025 to 2026https://www.pharmaradar360.com/article/menb-vaccine-bexsero-offer-autumn-2026-pgd-template-304b5c86eabf3910Pharma Surgeen2026-06-25T14:00:00.000ZMenB vaccine (Bexsero®) offer Autumn 2026: PGD templatehttps://www.pharmaradar360.com/article/gastrointestinal-infections-and-outbreak-statistics-for-england-05961f6c3dda1ec2Pharma Surgeen2026-06-25T14:00:00.000ZGastrointestinal infections and outbreak statistics for Englandhttps://www.pharmaradar360.com/article/immunisation-patient-group-direction-pgd-templates-1af7ede7c1c283c6Pharma Surgeen2026-06-25T14:00:00.000ZImmunisation patient group direction (PGD) templateshttps://www.pharmaradar360.com/article/united-therapeutics-uthr-is-more-than-a-single-drug-biotech-because-cash-flow-fu-9bdab9637e0b2adfPharma Surgeen2026-06-25T13:49:03.000ZUnited Therapeutics (UTHR) Is More Than a Single-Drug Biotech Because Cash Flow Funds a Broader Transplant Platformhttps://www.pharmaradar360.com/article/natera-and-eledon-announce-strategic-partnership-for-prosperatm-monitoring-in-pl-596d13a4b7c4c42dPharma Surgeen2026-06-25T13:44:57.000ZNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trialhttps://www.pharmaradar360.com/article/price-to-book-forward-of-krystal-biotech-inc-swb-4kb-62c3e1a2b4c5165bPharma Surgeen2026-06-25T13:25:23.000ZPrice to book forward of Krystal Biotech, Inc. – SWB:4KBhttps://www.pharmaradar360.com/article/dolcas-biotech-ceo-highlights-morikol-marine-collagen-science-and-delivery-forma-122452e97ce98dfcPharma Surgeen2026-06-25T13:22:21.000ZDolCas Biotech: CEO highlights Morikol marine collagen science and delivery format R&Dhttps://www.pharmaradar360.com/article/ladder17-podcast-how-exozymes-is-scaling-as-a-public-company-200173f56ee9d291Pharma Surgeen2026-06-25T13:09:02.000ZLadder17 podcast: How eXoZymes is Scaling as a Public Companyhttps://www.pharmaradar360.com/article/u-s-trade-probe-puts-german-drug-prices-under-the-microscope-as-health-innovatio-85899243976a2166Pharma Surgeen2026-06-25T13:05:22.000ZU.S. Trade Probe Puts German Drug Prices Under the Microscope as Health Innovations Advancehttps://www.pharmaradar360.com/article/israeli-founded-ai-biotech-immunai-launches-drug-discovery-collaboration-with-bo-397be0327eaf5310Pharma Surgeen2026-06-25T13:01:05.000ZIsraeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheimhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2025-to-2026-695ba9f5e6b7fd05Pharma Surgeen2026-06-25T13:00:01.000ZWeekly all-cause mortality surveillance: 2025 to 2026https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-06-25T13:00:01.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-06-25T13:00:01.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-06-25T13:00:01.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-06-25T13:00:01.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-06-25T13:00:01.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-06-25T13:00:01.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/is-upstream-bio-inc-upb-a-rising-biotech-opportunity-after-new-analyst-coverage-e6ba253937cf1877Pharma Surgeen2026-06-25T12:42:44.000ZIs Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?https://www.pharmaradar360.com/article/abl-bio-targets-december-phase-3-for-abl111-pursues-record-korea-deal-chosunbiz-f9b9344ffd5d70bePharma Surgeen2026-06-25T12:42:00.000ZAbl Bio targets December phase 3 for ABL111, pursues record Korea deal - CHOSUNBIZhttps://www.pharmaradar360.com/article/legend-biotech-corporation-legn-price-target-raised-to-49-on-lb5006-clinical-pro-cdab0ca54bc1e6ddPharma Surgeen2026-06-25T12:40:48.000ZLegend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progresshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-pharmala-biotech-holdings-inc-otc-mdxxf-385b21e18c534106Pharma Surgeen2026-06-25T12:25:57.000ZPrice to earnings forward of PharmAla Biotech Holdings Inc. – OTC:MDXXFhttps://www.pharmaradar360.com/article/fda-drops-blood-pressure-device-enforcement-against-whoop-41a3d1cd09ca8e10Pharma Surgeen2026-06-25T12:20:00.000ZFDA drops blood pressure device enforcement against Whoophttps://www.pharmaradar360.com/article/3-under-the-radar-biotech-takeover-targets-for-the-next-pharma-buying-spree-4a41de854878b86aPharma Surgeen2026-06-25T12:15:12.000Z3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spreehttps://www.pharmaradar360.com/article/analysing-key-trends-in-china-s-patent-linkage-system-and-their-impact-on-pharma-ec6c5c4d79588af4Pharma Surgeen2026-06-25T12:13:52.000ZAnalysing key trends in China’s patent linkage system and their impact on pharmaceutical patent strategieshttps://www.pharmaradar360.com/article/pharma-pulse-ups-s-cold-chain-buildout-and-abbvie-s-10-9b-immunology-bet-04d3b5b555ff8fa3Pharma Surgeen2026-06-25T12:12:44.000ZPharma Pulse: UPS's Cold Chain Buildout and AbbVie's $10.9B Immunology Bethttps://www.pharmaradar360.com/article/usc-surgeon-david-armstrong-to-lead-nu-3-diabetic-foot-ulcer-trial-94988d2b75b961dcPharma Surgeen2026-06-25T12:02:00.000ZUSC surgeon David Armstrong to lead Nu-3 diabetic foot ulcer trialhttps://www.pharmaradar360.com/article/protecting-patients-ensuring-safe-quality-and-effective-health-products-c170afbc043ac82fPharma Surgeen2026-06-25T12:01:09.000ZProtecting Patients: Ensuring Safe, Quality and Effective Health Productshttps://www.pharmaradar360.com/article/03592716625a124aPharma Surgeen2026-06-25T11:52:38.000ZΠΙΛΟΤΙΚΟ ΠΡΟΓΡΑΜΜΑ ΗΛΕΚΤΡΟΝΙΚΗΣ ΕΚΔΟΣΗΣ ΦΥΛΛΟΥ ΟΔΗΓΙΩΝ ΧΡΗΣΗΣ, ΦΑΡΜΑΚΩΝ ΑΝΘΡΩΠΙΝΗΣ ΧΡΗΣΗΣhttps://www.pharmaradar360.com/article/5-small-drug-stocks-to-invest-in-amid-a-biotech-comeback-f744fd2e24521b11Pharma Surgeen2026-06-25T11:48:02.000Z5 Small Drug Stocks to Invest in Amid a Biotech Comebackhttps://www.pharmaradar360.com/article/viking-therapeutics-starts-human-clinical-trials-for-new-obesity-drug-following-af2d1f3e1d7b4d8cPharma Surgeen2026-06-25T11:46:18.000ZViking Therapeutics Starts Human Clinical Trials For New Obesity Drug Following Federal Regulatory Clearancehttps://www.pharmaradar360.com/article/botulism-diagnosis-data-and-analysis-943c3264edccc127Pharma Surgeen2026-06-25T11:38:34.000ZBotulism: diagnosis, data and analysishttps://www.pharmaradar360.com/article/vivani-medical-receives-regulatory-approval-for-the-initiation-of-slim-1-a-phase-8a04eac5ac69378cPharma Surgeen2026-06-25T11:30:00.000ZVivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Managementhttps://www.pharmaradar360.com/article/fda-has-the-wrong-mission-that-s-why-it-fails-3bc4bccd0a8b6d4aPharma Surgeen2026-06-25T11:27:31.000ZFDA Has the Wrong Mission. That’s Why It Fails.https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-krystal-biotech-inc-nasdaq-krys-867a8b0412d7ec27Pharma Surgeen2026-06-25T11:07:34.000ZEnterprise value to EBIT forward of Krystal Biotech, Inc. – NASDAQ:KRYShttps://www.pharmaradar360.com/article/as-compounding-pharmacies-expand-patients-are-left-in-the-dark-about-drug-risks-994a866a7284bd85Pharma Surgeen2026-06-25T11:07:06.000ZAs compounding pharmacies expand, patients are left in the dark about drug riskshttps://www.pharmaradar360.com/article/q-a-the-reason-behind-lilly-s-pennsylvania-facility-aa8353b86ca117ebPharma Surgeen2026-06-25T11:03:18.000ZQ&A: The Reason Behind Lilly's Pennsylvania Facilityhttps://www.pharmaradar360.com/article/tiziana-announces-last-patient-successfully-dosed-in-its-phase-2-inform-ms-trial-776d6941dd04ed0aPharma Surgeen2026-06-25T11:00:00.000ZTiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trialhttps://www.pharmaradar360.com/article/eledon-trial-will-use-natera-s-prospera-test-to-track-kidney-rejection-0c1cf7019f6f19edPharma Surgeen2026-06-25T11:00:00.000ZEledon trial will use Natera’s Prospera test to track kidney rejectionhttps://www.pharmaradar360.com/article/atea-enrolls-880-plus-patients-in-global-hepatitis-c-trial-71a02ca3a6199edbPharma Surgeen2026-06-25T11:00:00.000ZAtea enrolls 880-plus patients in global hepatitis C trialhttps://www.pharmaradar360.com/article/natera-and-eledon-announce-strategic-partnership-for-prosperatm-monitoring-in-pl-8c0a1e393608c3b4Pharma Surgeen2026-06-25T11:00:00.000ZNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trialhttps://www.pharmaradar360.com/article/ionis-bags-30m-from-recordati-for-ex-us-rights-to-near-approval-rare-disease-pro-42847fcec46f2aa0Pharma Surgeen2026-06-25T10:59:22.000ZIonis bags $30M from Recordati for ex-US rights to near-approval rare disease prospecthttps://www.pharmaradar360.com/article/implementing-reporter-assay-based-mat-for-rapid-pyrogen-detection-8b81b2d0df440f0fPharma Surgeen2026-06-25T10:54:01.000ZImplementing reporter assay-based MAT for rapid pyrogen detectionhttps://www.pharmaradar360.com/article/adc-therapeutics-cuts-jobs-as-zynlonta-fda-talks-loom-0da62cecfc556d61Pharma Surgeen2026-06-25T10:46:37.000ZADC Therapeutics cuts jobs as Zynlonta FDA talks loomhttps://www.pharmaradar360.com/article/fda-approves-keytruda-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahy-9e3103fd262e9ca3Pharma Surgeen2026-06-25T10:45:00.000ZFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)https://www.pharmaradar360.com/article/what-medicare-part-d-patients-need-to-know-about-accessing-foundayo-orforglipron-495b5bc0715962aePharma Surgeen2026-06-25T10:45:00.000ZWhat Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementhttps://www.pharmaradar360.com/article/germany-s-merck-boosts-life-sciences-business-with-11-billion-bio-techne-deal-439433ef70682802Pharma Surgeen2026-06-25T10:39:48.000ZGermany's Merck boosts life sciences business with $11 billion Bio-Techne dealhttps://www.pharmaradar360.com/article/julie-kim-takes-top-job-at-takeda-after-weber-retirement-b4180ad723a22828Pharma Surgeen2026-06-25T10:36:34.000ZJulie Kim takes top job at Takeda after Weber retirementhttps://www.pharmaradar360.com/article/the-realities-of-pharmaceutical-onshoring-a-cdmo-perspective-97826e8a57c406d1Pharma Surgeen2026-06-25T10:29:48.000ZThe realities of pharmaceutical onshoring: a CDMO perspectivehttps://www.pharmaradar360.com/article/helus-pharma-help-prices-us-50m-share-sale-to-fund-phase-3-mdd-trial-d8ea228dd4ec6ea8Pharma Surgeen2026-06-25T10:28:24.000ZHelus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trialhttps://www.pharmaradar360.com/article/highs-and-lows-u-s-drug-prices-in-2025-30c6b0553826f540Pharma Surgeen2026-06-25T10:01:51.000ZHighs and Lows: U.S. Drug Prices in 2025https://www.pharmaradar360.com/article/remix-to-enter-nasdaq-through-passage-bio-reverse-merger-8376b2eb62b20bcbPharma Surgeen2026-06-25T10:01:41.000ZRemix to enter Nasdaq through Passage Bio reverse mergerhttps://www.pharmaradar360.com/article/bio-usa-abl-bio-ceo-sanghoon-lee-phase-3-gastric-cancer-drug-trial-to-begin-this-2d70dc937e4065b3Pharma Surgeen2026-06-25T09:49:46.000Z[BIO USA] ABL Bio CEO Sanghoon Lee: "Phase 3 Gastric Cancer Drug Trial to Begin This Year"https://www.pharmaradar360.com/article/yomiuri-takeda-pharmaceutical-s-weber-says-company-in-good-position-for-the-futu-047136d64315ff33Pharma Surgeen2026-06-25T09:48:00.000ZYomiuri: Takeda Pharmaceutical's Weber Says Company in 'Good Position for the Future' As He Steps Downhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-rtw-biotech-opportunities-ltd-usd-fwb-0bm-c2077f82544a2b0dPharma Surgeen2026-06-25T09:46:44.000ZPrice to sales forward of RTW Biotech Opportunities Ltd USD – FWB:0BMhttps://www.pharmaradar360.com/article/price-to-book-forward-of-biomarin-pharmaceutical-inc-gettex-bm8-3ee4a9848c61c8c4Pharma Surgeen2026-06-25T09:45:48.000ZPrice to book forward of BioMarin Pharmaceutical Inc. – GETTEX:BM8https://www.pharmaradar360.com/article/price-to-book-forward-of-feng-chi-biotech-corp-tpex-6744-77fa59a7cbfb2d98Pharma Surgeen2026-06-25T09:45:23.000ZPrice to book forward of Feng Chi Biotech Corp. – TPEX:6744https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-krystal-biotech-inc-nasdaq-krys-54c6a4113e936644Pharma Surgeen2026-06-25T09:34:32.000ZEnterprise value to revenue forward of Krystal Biotech, Inc. – NASDAQ:KRYShttps://www.pharmaradar360.com/article/pharmaceutical-regulatory-update-2026-eu-uk-fda-global-changes-explained-729ffc5c9f68e41cPharma Surgeen2026-06-25T09:34:02.000ZPharmaceutical regulatory update 2026: EU, UK, FDA & global changes explainedhttps://www.pharmaradar360.com/article/the-biotech-founder-asking-why-good-science-gets-stuck-c66cdcc4fc783570Pharma Surgeen2026-06-25T09:29:58.000ZThe biotech founder asking why good science gets stuckhttps://www.pharmaradar360.com/article/guidance-mhra-innovation-office-guidance-and-support-d55aaa5713ffae60Pharma Surgeen2026-06-25T09:16:18.000ZGuidance: MHRA Innovation Office: guidance and supporthttps://www.pharmaradar360.com/article/tracking-cathie-wood-major-ai-biotech-discovery-bet-on-recursion-heavy-reduction-513492f11d900cbePharma Surgeen2026-06-25T09:03:26.000ZTracking Cathie Wood: Major AI Biotech Discovery Bet on Recursion, Heavy Reduction in Absci Holdingshttps://www.pharmaradar360.com/article/bio-2026-how-nih-cuts-have-threatened-us-competitiveness-against-china-b4bc17e6dfc4e7caPharma Surgeen2026-06-25T09:03:05.000ZBIO 2026: How NIH cuts have threatened US competitiveness against Chinahttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stake-increased-by-sg-americas-securitie-4fddb2b2b48d6a0bPharma Surgeen2026-06-25T08:55:10.000ZTeva Pharmaceutical Industries Ltd. $TEVA Stake Increased by SG Americas Securities LLChttps://www.pharmaradar360.com/article/bio-2026-indiana-biopharma-investment-and-the-lilly-effect-2c0308532361277ePharma Surgeen2026-06-25T08:53:04.000ZBIO 2026: Indiana, biopharma investment and the Lilly effecthttps://www.pharmaradar360.com/article/abl-bio-is-launching-phase-3-global-clinical-trials-of-its-new-gastric-cancer-dr-0a6fe21423b25f84Pharma Surgeen2026-06-25T08:50:09.000ZABL Bio is launching phase 3 global clinical trials of its new gastric cancer drug "ABL111" within t..https://www.pharmaradar360.com/article/vaccine-schedule-change-helps-protect-babies-earlier-against-meningitis-b-9d70be5a1c71dee4Pharma Surgeen2026-06-25T08:50:00.000ZVaccine schedule change helps protect babies earlier against meningitis Bhttps://www.pharmaradar360.com/article/biosecure-didn-t-stop-china-s-rise-in-biotech-some-lawmakers-want-to-do-more-f301323cecb6df92Pharma Surgeen2026-06-25T08:30:49.000ZBiosecure didn’t stop China’s rise in biotech. Some lawmakers want to do morehttps://www.pharmaradar360.com/article/hsbc-holdings-plc-lowers-holdings-in-teva-pharmaceutical-industries-ltd-teva-7c8039a60abac925Pharma Surgeen2026-06-25T08:30:14.000ZHsbc Holdings PLC Lowers Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-06-25T08:30:11.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-06-25T08:30:11.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-06-25T08:30:11.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-06-25T08:30:11.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/tetanus-in-england-annual-reports-55f6cea4b8ae62acPharma Surgeen2026-06-25T08:30:06.000ZTetanus in England: annual reportshttps://www.pharmaradar360.com/article/pertussis-laboratory-confirmed-cases-reported-in-england-2025-aad4dec619bb9eebPharma Surgeen2026-06-25T08:30:06.000ZPertussis: laboratory confirmed cases reported in England 2025https://www.pharmaradar360.com/article/fungaemia-including-candidaemia-annual-data-from-voluntary-surveillance-edab4d6534b55584Pharma Surgeen2026-06-25T08:30:05.000ZFungaemia (including candidaemia): annual data from voluntary surveillancehttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9Pharma Surgeen2026-06-25T08:30:04.000ZCover of vaccination evaluated rapidly (COVER) programme 2025 to 2026: quarterly datahttps://www.pharmaradar360.com/article/epidemiology-of-covid-19-in-england-42b3d6340228a3a1Pharma Surgeen2026-06-25T08:30:01.000ZEpidemiology of COVID-19 in Englandhttps://www.pharmaradar360.com/article/childhood-vaccination-coverage-provisional-monthly-data-for-england-096cd364d32970b8Pharma Surgeen2026-06-25T08:30:00.000ZChildhood vaccination coverage: provisional monthly data for Englandhttps://www.pharmaradar360.com/article/record-hk-delegation-showcases-life-sciences-edge-in-san-diego-d2fe7fddc7b7a210Pharma Surgeen2026-06-25T08:12:28.000ZRecord HK delegation showcases life sciences edge in San Diegohttps://www.pharmaradar360.com/article/barometre-360-de-l-attractivite-de-la-france-pour-l-industrie-pharmaceutique-edi-19ff4524e0f1f3cbPharma Surgeen2026-06-25T08:12:20.000ZBaromètre 360° de l’attractivité de la France pour l’industrie pharmaceutique - Edition 2026 : Accès aux traitements, progrès thérapeutique, attractivité de la France : reprendre l’avantage ou décrocher ?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-biomarin-pharmaceutical-inc-nasdaq-bmrn-07de7e9244ed0d80Pharma Surgeen2026-06-25T08:07:27.000ZEnterprise value to EBITDA forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRNhttps://www.pharmaradar360.com/article/can-restaurants-charge-you-for-drinking-water-maharashtra-fda-s-new-order-says-71de6bd0b9d2b43bPharma Surgeen2026-06-25T07:58:59.000ZCan Restaurants Charge You For Drinking Water? Maharashtra FDA’s New Order Says…https://www.pharmaradar360.com/article/ipsen-recognized-at-lten-excellence-awards-2026-for-transforming-field-leadershi-1629ad33c263ee6fPharma Surgeen2026-06-25T07:57:06.000ZIpsen recognized at LTEN Excellence Awards 2026 for transforming field leadership through coachinghttps://www.pharmaradar360.com/article/are-you-working-with-cell-therapy-and-planning-a-clinical-trial-fa8ac360a3c2413fPharma Surgeen2026-06-25T07:52:00.000ZAre you working with cell therapy and planning a clinical trial?https://www.pharmaradar360.com/article/east-asia-s-biotech-autonomy-push-is-already-stunting-innovation-808f966407a0c507Pharma Surgeen2026-06-25T07:37:11.000ZEast Asia’s biotech autonomy push is already stunting innovationhttps://www.pharmaradar360.com/article/zepzelca-8340fbf8b145e16dPharma Surgeen2026-06-25T07:12:30.000ZZepzelcahttps://www.pharmaradar360.com/article/jazz-pharmaceuticals-zepzelca-misses-primary-endpoint-in-phase-3-lung-cancer-tri-48295a4697676f4fPharma Surgeen2026-06-25T07:02:45.000ZJazz Pharmaceuticals Zepzelca Misses Primary Endpoint in Phase 3 Lung Cancer Trialhttps://www.pharmaradar360.com/article/recordati-announces-license-agreement-with-ionis-pharmaceuticals-for-zilganersen-7e85659ea7fd2290Pharma Surgeen2026-06-25T06:59:07.000ZRECORDATI ANNOUNCES LICENSE AGREEMENT WITH IONIS PHARMACEUTICALS FOR ZILGANERSEN FOR THE TREATMENT OF ALEXANDER DISEASE IN ALL COUNTRIES OUTSIDE THE U.S.https://www.pharmaradar360.com/article/phathom-completes-enrollment-in-phase-2-vonoprazan-eoe-trial-ahead-of-schedule-3484446d89200c5fPharma Surgeen2026-06-25T06:53:04.000ZPhathom Completes Enrollment in Phase 2 Vonoprazan EoE Trial Ahead of Schedulehttps://www.pharmaradar360.com/article/fda-backs-entera-bio-s-phase-3-plan-for-oral-eb613-osteoporosis-drug-e2e36f34828d0b7ePharma Surgeen2026-06-25T06:53:04.000ZFDA Backs Entera Bio’s Phase 3 Plan for Oral EB613 Osteoporosis Drughttps://www.pharmaradar360.com/article/maharashtra-fda-bans-serving-food-in-newspapers-issues-statewide-food-safety-ord-b2a326d0eb8af15dPharma Surgeen2026-06-25T06:48:00.000ZMaharashtra FDA bans serving food in newspapers, issues statewide food safety orderhttps://www.pharmaradar360.com/article/eli-lilly-signs-new-partnership-deal-with-china-s-abbisko-84d661d5953aa368Pharma Surgeen2026-06-25T06:39:59.000ZEli Lilly signs new partnership deal with China's Abbiskohttps://www.pharmaradar360.com/article/matters-concerning-controlling-shareholders-etc-466420396ec1213cPharma Surgeen2026-06-25T06:30:00.000ZMatters Concerning Controlling Shareholders, Etc.https://www.pharmaradar360.com/article/atrasentan-06d83d835d0cce4bPharma Surgeen2026-06-25T06:27:51.000ZAtrasentanhttps://www.pharmaradar360.com/article/avacta-reports-platform-validating-data-with-faridoxorubicin-during-bio-internat-ab5b376dbfa750a1Pharma Surgeen2026-06-25T06:04:46.000ZAvacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conferencehttps://www.pharmaradar360.com/article/avacta-announces-u-s-fda-agreement-on-pivotal-trial-design-for-ava6000-in-patien-6d314ce54ca178b0Pharma Surgeen2026-06-25T06:02:40.000ZAvacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancerhttps://www.pharmaradar360.com/article/otsuka-announces-positive-phase-3b-results-for-centanafadine-in-adults-with-adhd-2a238bee4fc92a9fPharma Surgeen2026-06-25T06:00:00.000ZOtsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxietyhttps://www.pharmaradar360.com/article/bio-usa-korea-exchange-courts-global-biotech-ipos-at-bio-usa-434c7c1ea7a55566Pharma Surgeen2026-06-25T05:21:32.000Z[Bio USA] Korea Exchange courts global biotech IPOs at Bio USAhttps://www.pharmaradar360.com/article/comment-pharma-s-demand-for-innovation-is-powering-biotech-s-recovery-d502cdf52cfa4941Pharma Surgeen2026-06-25T05:17:06.000ZComment: Pharma’s demand for innovation is powering biotech’s recoveryhttps://www.pharmaradar360.com/article/al-s-pharma-presents-ap-101-phase-2-data-supporting-misfolded-sod1-as-a-therapeu-153ed301f5e7a41bPharma Surgeen2026-06-25T04:02:35.000ZAL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026https://www.pharmaradar360.com/article/patent-cliffs-aren-t-the-only-driver-of-biotech-m-a-boom-7473cfb85d33ed9aPharma Surgeen2026-06-25T04:00:30.000ZPatent cliffs aren’t the only driver of biotech M&A boomhttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-9a3365a8933f4fddPharma Surgeen2026-06-25T01:50:46.000ZUS FDA declines to approve Achieve Life Sciences' smoking-cessation drughttps://www.pharmaradar360.com/article/calcimedica-receives-fda-clearance-to-resume-auxora-clinical-trial-for-acute-kid-a17e837c30201ae7Pharma Surgeen2026-06-25T01:44:00.000ZCalciMedica Receives FDA Clearance to Resume Auxora Clinical Trial for Acute Kidney Injury After Safety Reviewhttps://www.pharmaradar360.com/article/safe-food-starts-with-awareness-fda-celebrates-world-food-safety-day-2026-bf4227d6dbe21a1dPharma Surgeen2026-06-25T01:36:09.000Z𝐒𝐀𝐅𝐄 𝐅𝐎𝐎𝐃 𝐒𝐓𝐀𝐑𝐓𝐒 𝐖𝐈𝐓𝐇 𝐀𝐖𝐀𝐑𝐄𝐍𝐄𝐒𝐒: 𝐅𝐃𝐀 𝐂𝐄𝐋𝐄𝐁𝐑𝐀𝐓𝐄𝐒 𝐖𝐎𝐑𝐋𝐃 𝐅𝐎𝐎𝐃 𝐒𝐀𝐅𝐄𝐓𝐘 𝐃𝐀𝐘 𝟐𝟎𝟐𝟔https://www.pharmaradar360.com/article/abu-dhabi-doh-partners-with-biocom-california-on-biotech-2a6cd88195bf1d3ePharma Surgeen2026-06-25T01:17:44.000ZAbu Dhabi DoH Partners with Biocom California on Biotechhttps://www.pharmaradar360.com/article/bio-usa-2026-pangen-biotech-eyes-europe-as-next-market-for-epo-biosimilar-590506cb4f14bef4Pharma Surgeen2026-06-25T00:52:25.000Z[BIO USA 2026] PanGen Biotech eyes Europe as next market for EPO biosimilarhttps://www.pharmaradar360.com/article/taiho-pharmaceutical-earns-first-silver-medal-in-ecovadis-sustainability-rating-f23b7c5652ce5258Pharma Surgeen2026-06-25T00:00:00.000ZTaiho Pharmaceutical Earns First Silver Medal in EcoVadis Sustainability Ratinghttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-38990f832f1792baPharma Surgeen2026-06-25T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-a78d79b064f14712Pharma Surgeen2026-06-25T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-d6bb36896399f72fPharma Surgeen2026-06-25T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-352f0a13c1333c21Pharma Surgeen2026-06-25T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-50739d6e77ad7cb8Pharma Surgeen2026-06-25T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-559b2a045643cfbcPharma Surgeen2026-06-25T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b2d826273c9db290Pharma Surgeen2026-06-25T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-d01e00d3d8ac1a26Pharma Surgeen2026-06-25T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-63a35a9221716570Pharma Surgeen2026-06-25T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-531c1f532eb05ea4Pharma Surgeen2026-06-25T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-a0b0d57cb542e9abPharma Surgeen2026-06-25T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b4ca0ba71b2b7ce9Pharma Surgeen2026-06-25T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-29e0518b1873af45Pharma Surgeen2026-06-25T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-4c70fcf6a732f5b6Pharma Surgeen2026-06-25T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/sterigenics-u-s-llc-filing-of-food-additive-petition-bc472b5373fba08bPharma Surgeen2026-06-25T00:00:00.000ZSterigenics U.S., LLC; Filing of Food Additive Petitionhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-cf30b759aa9248fdPharma Surgeen2026-06-25T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/government-owned-inventions-available-for-license-c8166-45-cell-line-427447d67509dcd6Pharma Surgeen2026-06-25T00:00:00.000ZGovernment Owned Inventions Available for License: C8166-45 Cell Linehttps://www.pharmaradar360.com/article/government-owned-inventions-available-for-license-compositions-and-methods-for-p-92fb7a0282013563Pharma Surgeen2026-06-25T00:00:00.000ZGovernment Owned Inventions Available for License: Compositions and Methods for Producing Dendritic Cell-based Vaccines With Enhanced Efficacyhttps://www.pharmaradar360.com/article/proposed-information-collection-activity-national-and-state-survey-of-child-and-d57cf429230cd62cPharma Surgeen2026-06-25T00:00:00.000ZProposed Information Collection Activity; National and State Survey of Child and Adolescent Well-Being (NSSCAW): Site Recruitment and Baseline Data Collectionhttps://www.pharmaradar360.com/article/notice-of-proposed-purchased-referred-care-delivery-area-redesignation-for-the-k-33c1ade47720f715Pharma Surgeen2026-06-25T00:00:00.000ZNotice of Proposed Purchased/Referred Care Delivery Area Redesignation for the Kewa Pueblohttps://www.pharmaradar360.com/article/order-under-sections-362-and-365-of-the-public-health-service-act-continuing-the-0688b7bbae0eedc4Pharma Surgeen2026-06-25T00:00:00.000ZOrder Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Existshttps://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-85d408578e78ccf1Pharma Surgeen2026-06-25T00:00:00.000ZNational Vaccine Injury Compensation Program; List of Petitions Receivedhttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-2be17aa3a65e9432Pharma Surgeen2026-06-25T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/cleveland-clinic-announces-early-planning-for-next-phase-of-main-campus-master-p-504a042f06249c34Pharma Surgeen2026-06-25T00:00:00.000ZCleveland Clinic Announces Early Planning for Next Phase of Main Campus Master Planhttps://www.pharmaradar360.com/article/incidental-electrocardiographic-recognition-of-left-anterior-fascicular-block-wi-6d0c925cbd3cd0ebPharma Surgeen2026-06-25T00:00:00.000ZIncidental Electrocardiographic Recognition of Left Anterior Fascicular Block With Delayed Troponin Elevation: A Case Report With Clinical Correlationhttps://www.pharmaradar360.com/article/the-multifaceted-role-of-bile-acids-in-breast-cancer-pathogenesis-therapeutic-po-6b939b39bd8297b5Pharma Surgeen2026-06-25T00:00:00.000ZThe multifaceted role of bile acids in breast cancer: pathogenesis, therapeutic potential, and drug deliveryhttps://www.pharmaradar360.com/article/clinical-practice-guideline-of-pet-ct-and-pet-mr-in-lymphoma-2025-edition-93293b0e34a8336cPharma Surgeen2026-06-25T00:00:00.000ZClinical practice guideline of PET/CT and PET/MR in lymphoma (2025 edition)https://www.pharmaradar360.com/article/global-pharmaceutical-market-evolution-from-blockbuster-drugs-to-biologics-and-b-426ce81dfecbd711Pharma Surgeen2026-06-25T00:00:00.000ZGlobal Pharmaceutical Market Evolution: From Blockbuster Drugs to Biologics and Biosimilars – A Comprehensive Reviewhttps://www.pharmaradar360.com/article/murder-most-foul-the-belfast-judge-s-daughter-and-the-scottish-raf-engineer-827ee29ccb858ff2Pharma Surgeen2026-06-25T00:00:00.000ZMurder most foul: the Belfast judge’s daughter and the Scottish RAF engineerhttps://www.pharmaradar360.com/article/harnessing-minimal-residual-disease-for-precision-medicine-in-locally-advanced-g-8445d72d01f197d5Pharma Surgeen2026-06-25T00:00:00.000ZHarnessing minimal residual disease for precision medicine in locally advanced gastric cancerhttps://www.pharmaradar360.com/article/effect-of-fusidic-acid-phonophoresis-as-a-complementary-therapy-in-chronic-rhino-530bb5b57a7611ccPharma Surgeen2026-06-25T00:00:00.000ZEffect of fusidic acid phonophoresis as a complementary therapy in chronic rhinosinusitis: a randomised clinical trialhttps://www.pharmaradar360.com/article/the-integration-of-new-technologies-in-diabetes-care-a-review-of-clinical-applic-20f24b31a8604791Pharma Surgeen2026-06-25T00:00:00.000ZTHE INTEGRATION OF NEW TECHNOLOGIES IN DIABETES CARE: A REVIEW OF CLINICAL APPLICATIONS AND OUTCOMEShttps://www.pharmaradar360.com/article/cross-cultural-adaptation-and-psychometric-evaluation-of-the-arabic-clinical-rea-30e1370168e03909Pharma Surgeen2026-06-25T00:00:00.000ZCross-Cultural Adaptation and Psychometric Evaluation of the Arabic Clinical Reasoning Scale Among Nursing Studentshttps://www.pharmaradar360.com/article/data-driven-clinical-phenotyping-of-adult-epilepsy-using-latent-class-analysis-a-36126bfe9c0c430aPharma Surgeen2026-06-25T00:00:00.000ZData-Driven Clinical Phenotyping of Adult Epilepsy Using Latent Class Analysis: A Regional Cohort Study from Southern Kazakhstanhttps://www.pharmaradar360.com/article/artificial-intelligence-assisted-detection-of-the-elongated-styloid-process-on-d-cfafa96f6aed8c7fPharma Surgeen2026-06-25T00:00:00.000ZArtificial Intelligence-Assisted Detection of the Elongated Styloid Process on Dental Radiographic Images: A Systematic Review and Literature Updatehttps://www.pharmaradar360.com/article/trastuzumab-emtansine-associated-porto-sinusoidal-vascular-disorder-clinical-fea-7fc44b06756c6645Pharma Surgeen2026-06-25T00:00:00.000ZTrastuzumab Emtansine–Associated Porto-Sinusoidal Vascular Disorder: Clinical Features and Outcomes from Published Caseshttps://www.pharmaradar360.com/article/not-all-microbiomes-reflect-chronic-pain-evidence-from-the-urinary-tract-in-a-ca-e0e933564f902305Pharma Surgeen2026-06-25T00:00:00.000ZNot All Microbiomes Reflect Chronic Pain: Evidence from the Urinary Tract in a Case–Control Studyhttps://www.pharmaradar360.com/article/dynamic-voice-optimization-after-type-i-thyroplasty-using-a-novel-adjustable-imp-bd534c20b5d8221cPharma Surgeen2026-06-25T00:00:00.000ZDynamic Voice Optimization After Type I Thyroplasty Using a Novel Adjustable Implant: A Prospective Longitudinal Studyhttps://www.pharmaradar360.com/article/professional-roles-and-work-related-challenges-of-anti-drug-social-workers-in-co-bd04354e677a574aPharma Surgeen2026-06-25T00:00:00.000ZProfessional Roles and Work-Related Challenges of Anti-Drug Social Workers in Community-Based Drug Rehabilitation: A Systematic Reviewhttps://www.pharmaradar360.com/article/integrating-physiatry-and-palliative-care-in-outpatient-oncology-a-clinical-fram-a1ff7ec4e7d1e7bePharma Surgeen2026-06-25T00:00:00.000ZIntegrating Physiatry and Palliative Care in Outpatient Oncology: A Clinical Framework for Bidirectional Referral and Co-Managementhttps://www.pharmaradar360.com/article/sedentarism-exhibits-a-distinct-mitochondrial-bioenergetic-phenotype-detectable-92463f7952f2a487Pharma Surgeen2026-06-25T00:00:00.000ZSedentarism Exhibits a Distinct Mitochondrial Bioenergetic Phenotype Detectable by Cardiopulmonary Exercise and Lactate Testing (CPELT)https://www.pharmaradar360.com/article/trial-of-fasteddy-simulation-of-building-induced-airflow-and-the-comparison-with-bbe8f0523c91021dPharma Surgeen2026-06-25T00:00:00.000ZTrial of FastEddy Simulation of Building-Induced Airflow and the Comparison with LIDAR and Flight Data in an Operating Airporthttps://www.pharmaradar360.com/article/k-anonymity-decay-in-multi-turn-clinical-large-language-model-conversations-29d79348ad2a68acPharma Surgeen2026-06-25T00:00:00.000ZK-anonymity decay in multi-turn clinical large language model conversationshttps://www.pharmaradar360.com/article/chronic-viral-hepatitis-with-concurrent-masld-dual-etiology-challenges-f6acd75936a77d08Pharma Surgeen2026-06-25T00:00:00.000ZChronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challengeshttps://www.pharmaradar360.com/article/clinical-utility-of-liquid-biopsy-in-biliary-tract-cancer-diagnosis-to-treatment-95dee60488f87c55Pharma Surgeen2026-06-25T00:00:00.000ZClinical utility of liquid biopsy in biliary tract cancer: Diagnosis to treatment monitoringhttps://www.pharmaradar360.com/article/correcao-de-apinhamento-dentario-associado-a-desvio-de-linha-media-por-meio-de-a-0970bac161a4bbd6Pharma Surgeen2026-06-25T00:00:00.000ZCorreção de apinhamento dentário, associado a desvio de linha média, por meio de alinhadores impressos em 3D com memória de forma sem uso de attachments: Relato de caso clínicohttps://www.pharmaradar360.com/article/peer-review-report-for-viral-hepatitis-and-liver-disease-in-the-mongolian-commun-cec885b18e220cbaPharma Surgeen2026-06-25T00:00:00.000ZPeer Review Report For: Viral hepatitis and liver disease in the Mongolian community in London ('MoLo'): A mixed methods study protocol to investigate the epidemiology and burden of disease to inform clinical and public health interventions [version 1; peer review: 2 approved]https://www.pharmaradar360.com/article/prediction-model-for-severe-complications-in-patients-with-failed-conservative-t-6349b9a9c94dcc1cPharma Surgeen2026-06-25T00:00:00.000ZPrediction Model for Severe Complications in Patients with Failed Conservative Treatment of Acute Intestinal Obstruction Based on Clinical and Imaging Features: Development and Validationhttps://www.pharmaradar360.com/article/clinical-pharmacology-of-heart-failure-in-frailty-0dd3bd3632b0a513Pharma Surgeen2026-06-25T00:00:00.000ZClinical Pharmacology of Heart Failure in Frailtyhttps://www.pharmaradar360.com/article/management-of-catatonia-in-parkinson-s-disease-with-comorbid-bipolar-disorder-a-4f6074542e9aed24Pharma Surgeen2026-06-25T00:00:00.000ZManagement of catatonia in Parkinson’s disease with comorbid bipolar disorder: A case report and review of literaturehttps://www.pharmaradar360.com/article/pharmaceutical-import-landscape-in-ethiopia-a-cross-sectional-study-of-importers-2601ad284ca57be3Pharma Surgeen2026-06-25T00:00:00.000ZPharmaceutical import landscape in Ethiopia: a cross-sectional study of importers’ perspectives on business and regulatory challengeshttps://www.pharmaradar360.com/article/pre-emptive-treatment-in-later-onset-urea-cycle-disorders-a-clinical-perspective-bab37f6a8edafdeaPharma Surgeen2026-06-25T00:00:00.000ZPre-emptive treatment in later-onset urea cycle disorders: a clinical perspective on glycerol phenylbutyratehttps://www.pharmaradar360.com/article/fibroblast-activity-biomarkers-are-associated-with-mortality-in-severe-covid-19-f0a3f053109b2d9fPharma Surgeen2026-06-25T00:00:00.000ZFibroblast activity biomarkers are associated with mortality in severe COVID-19: a post-hoc analysis of a phase 2 clinical trialhttps://www.pharmaradar360.com/article/efficacy-of-codesigned-covid-19-booster-vaccine-promotion-materials-for-long-ter-bacc27046b290616Pharma Surgeen2026-06-25T00:00:00.000ZEfficacy of codesigned COVID-19 booster vaccine promotion materials for long-term care staff: a cluster-randomized trialhttps://www.pharmaradar360.com/article/associations-of-anthropometric-related-phenotypes-with-functional-and-clinical-o-4a1a24d6487a7a93Pharma Surgeen2026-06-25T00:00:00.000ZAssociations of anthropometric-related phenotypes with functional and clinical outcomes in community-dwelling older adults: a cross-sectional analysis of ELSI-Brazilhttps://www.pharmaradar360.com/article/microbial-profile-and-antimicrobial-resistance-patterns-in-clinical-specimens-fr-a6665cc69c6f0e8ePharma Surgeen2026-06-25T00:00:00.000ZMicrobial profile and antimicrobial resistance patterns in clinical specimens from a secondary-level hospital in Accra, Ghana: a five-year retrospective studyhttps://www.pharmaradar360.com/article/determinants-of-out-of-home-activity-in-older-adults-with-cognitive-impairment-f-f9c8f27d40bc767fPharma Surgeen2026-06-25T00:00:00.000ZDeterminants of out-of-home activity in older adults with cognitive impairment following inpatient rehabilitation: A secondary cross-sectional analysis of a randomised controlled trial using location-based and accelerometer-derived measureshttps://www.pharmaradar360.com/article/redefining-radiotherapy-the-gut-as-an-active-target-in-immuno-oncology-0c225e58362951dePharma Surgeen2026-06-25T00:00:00.000ZRedefining Radiotherapy: The Gut as an Active Target in Immuno-oncologyhttps://www.pharmaradar360.com/article/medical-student-experience-with-an-8-week-online-mindfulness-training-program-qu-7d9cfccbd29af109Pharma Surgeen2026-06-25T00:00:00.000ZMedical student experience with an 8-week online mindfulness training program: Qualitative findings from a mixed-method randomised controlled trialhttps://www.pharmaradar360.com/article/effectiveness-of-a-chronic-care-model-based-transitional-care-program-for-patien-65dbc28a8bd5ffb2Pharma Surgeen2026-06-25T00:00:00.000ZEffectiveness of a chronic care model-based transitional care program for patients with biliary drainage: a randomized controlled trialhttps://www.pharmaradar360.com/article/less-is-more-an-analysis-of-postoperative-outcomes-comparing-low-dose-e-coli-der-21fc9c746a5baf04Pharma Surgeen2026-06-25T00:00:00.000ZLess Is More! An Analysis of Postoperative Outcomes Comparing Low-Dose E. Coli-Derived rhBMP-2 and Mammalian rhBMP-2 in Lateral Lumbar Spinal Fusion Surgeryhttps://www.pharmaradar360.com/article/start-stop-amp-select-the-steward-s-hat-trick-9339f70ac6f680f1Pharma Surgeen2026-06-25T00:00:00.000ZStart, Stop & Select: The Steward's Hat Trickhttps://www.pharmaradar360.com/article/advancing-beyond-stand-alone-nab-assays-perspectives-and-regulatory-impact-of-ap-1d34718bfa8157d9Pharma Surgeen2026-06-25T00:00:00.000ZAdvancing beyond stand-alone NAb assays: perspectives and regulatory impact of applying integrated immunogenicity assessment in drug developmenthttps://www.pharmaradar360.com/article/navigating-pd-l1-testing-in-immuno-oncology-analytical-robustness-clinical-valid-6d51e9169e43d24ePharma Surgeen2026-06-25T00:00:00.000ZNavigating PD-L1 testing in immuno-oncology: analytical robustness, clinical validation, and the role of the VENTANA SP263 assayhttps://www.pharmaradar360.com/article/interrelating-strategy-and-architecture-moves-a-clinical-inquiry-into-a-strategi-e303166497a4e5c7Pharma Surgeen2026-06-25T00:00:00.000ZInterrelating strategy and architecture moves: a clinical inquiry into a strategic digital initiativehttps://www.pharmaradar360.com/article/comparison-of-radiation-exposure-on-the-control-panel-side-versus-the-opposite-s-74988726fa743654Pharma Surgeen2026-06-25T00:00:00.000ZComparison of Radiation Exposure on the Control Panel Side Versus the Opposite Side During C-Arm Fluoroscopy-Guided Blocks: Randomized Controlled Trialhttps://www.pharmaradar360.com/article/a-nationwide-histopathology-study-reflecting-the-impact-of-the-introduction-of-m-1ed5235830cca92cPharma Surgeen2026-06-25T00:00:00.000ZA nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical carehttps://www.pharmaradar360.com/article/management-of-venous-thromboembolism-in-france-a-nationwide-clinical-practice-su-94cf9999514b7733Pharma Surgeen2026-06-25T00:00:00.000ZManagement of venous thromboembolism in France – a nationwide clinical practice survey among vascular medicine specialistshttps://www.pharmaradar360.com/article/associations-of-length-of-stay-with-sarcopenia-parameters-in-geriatric-patients-8b59535c257ea729Pharma Surgeen2026-06-25T00:00:00.000ZAssociations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest oldhttps://www.pharmaradar360.com/article/tumor-organoid-platform-design-for-drug-response-modeling-culture-architecture-m-14be896b81287737Pharma Surgeen2026-06-25T00:00:00.000ZTumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readoutshttps://www.pharmaradar360.com/article/cone-beam-computed-tomography-based-oropharyngeal-airway-narrowing-assessment-a-3fb6987c5a34d0ecPharma Surgeen2026-06-25T00:00:00.000ZCone-Beam Computed Tomography-Based Oropharyngeal Airway Narrowing Assessment: A Systematic Review of Methodologies, Measurements, and Clinical Associationshttps://www.pharmaradar360.com/article/out-of-field-and-in-field-teachers-professional-learning-gains-on-fostering-unde-4579f7c8520ce7caPharma Surgeen2026-06-25T00:00:00.000ZOut-of-field and in-field teachers’ professional learning gains on fostering understanding of multiplication: A randomized controlled trialhttps://www.pharmaradar360.com/article/surgical-strategies-and-long-term-survival-for-third-ventricle-chordoid-gliomas-a18bea32bb14a792Pharma Surgeen2026-06-25T00:00:00.000ZSurgical strategies and long-term survival for third ventricle chordoid gliomas: a systematic review and clinical algorithmhttps://www.pharmaradar360.com/article/effectiveness-of-low-level-laser-therapy-compared-to-standard-postoperative-care-fb51c48f8bccd6edPharma Surgeen2026-06-25T00:00:00.000ZEffectiveness of low-level laser therapy compared to standard postoperative care on pain intensity and cesarean section wound healing in the immediate postoperative period: a randomized clinical trialhttps://www.pharmaradar360.com/article/unraveling-clade-specific-differences-in-candida-auris-evolution-adaptation-and-5b12ac2781366bc7Pharma Surgeen2026-06-25T00:00:00.000ZUnraveling clade-specific differences in Candida auris: evolution, adaptation, and pathogenicityhttps://www.pharmaradar360.com/article/adjunctive-postoperative-vitamin-b-complex-with-ibuprofen-for-pain-and-soft-tiss-f6016f4f963808b3Pharma Surgeen2026-06-25T00:00:00.000ZAdjunctive postoperative vitamin B complex with ibuprofen for pain and soft-tissue healing after impacted mandibular third molar surgery: a split-mouth randomized clinical trialhttps://www.pharmaradar360.com/article/iridology-biological-plausibility-clinical-evidence-and-implications-for-ophthal-84241c297aa38011Pharma Surgeen2026-06-25T00:00:00.000ZIridology: Biological plausibility, clinical evidence, and implications for ophthalmic practicehttps://www.pharmaradar360.com/article/unveiling-dry-eye-disease-prior-to-cataract-surgery-a-multicenter-clinical-study-1bc5250a09c94136Pharma Surgeen2026-06-25T00:00:00.000ZUnveiling dry eye disease prior to cataract surgery: A multicenter clinical studyhttps://www.pharmaradar360.com/article/severe-pediatric-snakebite-with-coagulopathy-and-compartment-syndrome-conservati-7db2cdede4d795c9Pharma Surgeen2026-06-25T00:00:00.000ZSevere Pediatric Snakebite With Coagulopathy and Compartment Syndrome: Conservative Management With Plasma Exchangehttps://www.pharmaradar360.com/article/intentional-replantation-with-apical-periodontal-ligament-preservation-a-case-re-8e99cf66b74db539Pharma Surgeen2026-06-25T00:00:00.000ZIntentional replantation with apical periodontal ligament preservation: A case reporthttps://www.pharmaradar360.com/article/nct07669792-khoury-s-bone-shell-technique-versus-titanium-reinforced-polytetrafl-5aa02ee69ae1fc91Pharma Surgeen2026-06-25T00:00:00.000ZNCT07669792: Khoury's Bone Shell Technique Versus Titanium-Reinforced Polytetrafluoroethylene for Augmentation of Horizontal Deficiency in Posterior Mandible (Histomorphometry Analysis): A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/nct07669402-comparative-evaluation-of-letrozole-l-carnitine-and-combination-ther-a2d7b63a296a4c32Pharma Surgeen2026-06-25T00:00:00.000ZNCT07669402: Comparative Evaluation of Letrozole, L-Carnitine, and Combination Therapy on Sperm Quality and ART Outcomes in Idiopathic Oligoasthenoteratozoospermia: A Three-Arm Randomized Trialhttps://www.pharmaradar360.com/article/nct07669324-effect-of-chemical-and-light-bleaching-techniques-on-color-change-de-47f128330aafadbfPharma Surgeen2026-06-25T00:00:00.000ZNCT07669324: Effect of Chemical and Light Bleaching Techniques on Color Change, Dentin Hypersensitivity and Patient Satisfactionhttps://www.pharmaradar360.com/article/nct07669129-the-effect-of-full-versus-partial-coverage-thermoformed-retainers-in-aec34fa3e5bad6ebPharma Surgeen2026-06-25T00:00:00.000ZNCT07669129: The Effect of Full Versus Partial Coverage Thermoformed Retainers in Dual Retention With a Lower Bonded Retainer, on Periodontal, Orthodontic, and Patient-Reported Outcomeshttps://www.pharmaradar360.com/article/nct07669103-bone-cancer-surgery-prospective-database-95d2994ec51da7cfPharma Surgeen2026-06-25T00:00:00.000ZNCT07669103: Bone Cancer Surgery Prospective Databasehttps://www.pharmaradar360.com/article/nct07668570-sbrt-plus-ql1706-as-second-line-therapy-for-hepatocellular-carcinoma-f62d0e2f6838ae43Pharma Surgeen2026-06-25T00:00:00.000ZNCT07668570: SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinomahttps://www.pharmaradar360.com/article/nct07668388-a-research-study-comparing-how-well-different-doses-of-the-medicine-aabc8af74060aa10Pharma Surgeen2026-06-25T00:00:00.000ZNCT07668388: A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabeteshttps://www.pharmaradar360.com/article/nct07668375-outcome-of-treatment-with-botulinum-toxina-in-patients-with-temporom-9a76b853519b22d1Pharma Surgeen2026-06-25T00:00:00.000ZNCT07668375: Outcome of Treatment With Botulinum toxinA in Patients With Temporomandibular Myofascial Painhttps://www.pharmaradar360.com/article/nct07667699-multidimensional-determinants-of-functional-health-in-women-aged-45-9b84ed3de1c7ed76Pharma Surgeen2026-06-25T00:00:00.000ZNCT07667699: Multidimensional Determinants of Functional Health In Women Aged 45-60https://www.pharmaradar360.com/article/nct07667361-time-to-healthy-lifestyle-habit-using-digital-health-tools-in-adults-26d35f2b024b95ccPharma Surgeen2026-06-25T00:00:00.000ZNCT07667361: Time to Healthy Lifestyle Habit Using Digital Health Tools in Adults at Risk of Diabeteshttps://www.pharmaradar360.com/article/nct07613099-fibrotic-disease-activity-in-cardiopulmonary-disorders-using-18f-fib-d3d2836ef9a19c9fPharma Surgeen2026-06-25T00:00:00.000ZNCT07613099: Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaginghttps://www.pharmaradar360.com/article/nct07574541-multitargeted-recombinant-ad5-psa-muc-1-brachyury-based-immunotherap-0f3af0b930fedd23Pharma Surgeen2026-06-25T00:00:00.000ZNCT07574541: Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillancehttps://www.pharmaradar360.com/article/nct07504601-investigating-the-analgesic-potential-of-2r-6r-hnk-in-acute-pain-in-7d802ea0b5cc5a4ePharma Surgeen2026-06-25T00:00:00.000ZNCT07504601: Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteershttps://www.pharmaradar360.com/article/nct07488923-a-first-in-human-fih-phase-1-study-of-ml261-an-autologous-potency-en-92bdadcf262e08c2Pharma Surgeen2026-06-25T00:00:00.000ZNCT07488923: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)https://www.pharmaradar360.com/article/nct07437976-a-natural-history-of-genetic-and-environmental-predictors-of-puberta-6b2ccb1e0c1c166dPharma Surgeen2026-06-25T00:00:00.000ZNCT07437976: A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesityhttps://www.pharmaradar360.com/article/nct07424157-long-term-follow-up-of-subjects-treated-with-seattle-children-s-ther-0a2f776ca3ba94d9Pharma Surgeen2026-06-25T00:00:00.000ZNCT07424157: Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Productshttps://www.pharmaradar360.com/article/nct07223398-shared-decision-making-to-treat-or-prevent-stop-hiv-in-criminal-lega-f4aa5faef1c3c4eaPharma Surgeen2026-06-25T00:00:00.000ZNCT07223398: Shared Decision Making to Treat Or Prevent (STOP) HIV in Criminal Legal Involved Populations (R33)https://www.pharmaradar360.com/article/nct07216482-a-clinical-study-of-enlicitide-in-participants-with-high-cholesterol-97fbb59c25be5a0cPharma Surgeen2026-06-25T00:00:00.000ZNCT07216482: A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)https://www.pharmaradar360.com/article/nct07003542-a-phase-2-and-pharmacodynamic-study-of-sitagliptin-in-patients-with-758db71a864ccca7Pharma Surgeen2026-06-25T00:00:00.000ZNCT07003542: A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomashttps://www.pharmaradar360.com/article/nct06963580-efficacy-of-mi078-capsules-in-treating-postpartum-depression-1bff0e7567fd53d7Pharma Surgeen2026-06-25T00:00:00.000ZNCT06963580: Efficacy of MI078 Capsules in Treating Postpartum Depressionhttps://www.pharmaradar360.com/article/nct06745024-comparing-radiation-therapy-to-usual-treatment-for-patients-with-hig-a770bfa4bbdd005dPharma Surgeen2026-06-25T00:00:00.000ZNCT06745024: Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trialhttps://www.pharmaradar360.com/article/nct06694454-neoadjuvant-inhaled-azacytidine-with-platinum-based-chemotherapy-and-0c2ce5ad67f1e6f8Pharma Surgeen2026-06-25T00:00:00.000ZNCT06694454: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct06463080-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-6da9ebef6578e0d5Pharma Surgeen2026-06-25T00:00:00.000ZNCT06463080: [Trial of device that is not approved or cleared by the U.S. FDA]https://www.pharmaradar360.com/article/nct06221046-testing-the-safety-and-efficacy-of-a-novel-barrier-cream-for-the-tre-956eeddc7e09de82Pharma Surgeen2026-06-25T00:00:00.000ZNCT06221046: Testing the Safety and Efficacy of a Novel Barrier Cream for the Treatment of Moisture Associated Skin Damagehttps://www.pharmaradar360.com/article/nct06052631-microneurographic-assessment-of-peripheral-nerves-in-healthy-volunte-19ef87b4db826563Pharma Surgeen2026-06-25T00:00:00.000ZNCT06052631: Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Genehttps://www.pharmaradar360.com/article/nct06041503-enfortumab-vedotin-with-or-without-pembrolizumab-in-rare-genitourina-4bdb85c09a6ddf07Pharma Surgeen2026-06-25T00:00:00.000ZNCT06041503: Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)https://www.pharmaradar360.com/article/nct05848622-gait-rehabilitation-to-treat-fastoa-1f1da2173a91188ePharma Surgeen2026-06-25T00:00:00.000ZNCT05848622: Gait Rehabilitation to Treat FastOAhttps://www.pharmaradar360.com/article/nct05742802-long-term-efficacy-and-safety-of-tozorakimab-in-participants-with-ch-22de2ed9981c8695Pharma Surgeen2026-06-25T00:00:00.000ZNCT05742802: Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).https://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459Pharma Surgeen2026-06-25T00:00:00.000ZNCT05713799: Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesityhttps://www.pharmaradar360.com/article/nct05713071-evaluation-of-bariatric-endoscopic-antral-myotomy-beam-as-a-treatmen-73ccc56f8fae17dePharma Surgeen2026-06-25T00:00:00.000ZNCT05713071: Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesityhttps://www.pharmaradar360.com/article/nct05673200-testing-the-addition-of-an-anti-cancer-drug-astx727-cedazuridine-dec-1b9ece8eb5597ee7Pharma Surgeen2026-06-25T00:00:00.000ZNCT05673200: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancerhttps://www.pharmaradar360.com/article/nct05521854-contingency-management-for-drug-use-does-age-matter-08384dece3cead54Pharma Surgeen2026-06-25T00:00:00.000ZNCT05521854: Contingency Management for Drug Use: Does Age Matter?https://www.pharmaradar360.com/article/nct05450250-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-a1751d319f927c5bPharma Surgeen2026-06-25T00:00:00.000ZNCT05450250: [Trial of device that is not approved or cleared by the U.S. FDA]https://www.pharmaradar360.com/article/nct05277051-first-time-in-human-study-of-gsk4381562-in-participants-with-advance-adad0ce535af7064Pharma Surgeen2026-06-25T00:00:00.000ZNCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct05050162-comparing-cisplatin-every-three-weeks-to-cisplatin-weekly-when-combi-b493ce9f4e41a219Pharma Surgeen2026-06-25T00:00:00.000ZNCT05050162: Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancerhttps://www.pharmaradar360.com/article/nct04573140-a-study-of-rna-lipid-particle-rna-lp-vaccines-for-newly-diagnosed-pe-28b7dbda1fd99691Pharma Surgeen2026-06-25T00:00:00.000ZNCT04573140: A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)https://www.pharmaradar360.com/article/nct04321954-lenvatinib-in-locally-advanced-invasive-thyroid-cancer-f74eeac5f747bcecPharma Surgeen2026-06-25T00:00:00.000ZNCT04321954: Lenvatinib in Locally Advanced Invasive Thyroid Cancerhttps://www.pharmaradar360.com/article/nct04269902-testing-early-treatment-for-patients-with-high-risk-chronic-lymphocy-cf81092206932f4ePharma Surgeen2026-06-25T00:00:00.000ZNCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Studyhttps://www.pharmaradar360.com/article/nct02211768-transformation-of-plexiform-neurofibromas-to-malignant-peripheral-ne-798abe7fe26ea5fdPharma Surgeen2026-06-25T00:00:00.000ZNCT02211768: Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1https://www.pharmaradar360.com/article/nct00895271-establishing-fibroblast-derived-cell-lines-from-skin-biopsies-of-pat-e8722c34f1e3ca58Pharma Surgeen2026-06-25T00:00:00.000ZNCT00895271: Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disordershttps://www.pharmaradar360.com/article/revolution-medicines-puts-pancreatic-cancer-combo-data-on-esmo-stage-efd627f97c211058Pharma Surgeen2026-06-24T23:31:00.000ZRevolution Medicines puts pancreatic cancer combo data on ESMO stagehttps://www.pharmaradar360.com/article/onconic-ceo-targets-u-s-fda-phase-3-filing-for-zacuvo-this-year-55c3f1377ea70160Pharma Surgeen2026-06-24T22:03:05.000ZOnconic CEO Targets U.S. FDA Phase 3 Filing for Zacuvo This Yearhttps://www.pharmaradar360.com/article/drug-maker-sues-to-halt-implementation-of-arkansas-new-pharmaceutical-distributi-8f8f4fa7e404a914Pharma Surgeen2026-06-24T21:25:00.000ZDrug maker sues to halt implementation of Arkansas’ new pharmaceutical distribution lawhttps://www.pharmaradar360.com/article/the-challenges-bringing-pharma-and-biotech-manufacturing-back-to-the-u-s-cf9dfcb0d97474efPharma Surgeen2026-06-24T21:21:57.000ZThe Challenges Bringing Pharma and Biotech Manufacturing Back to the U.S.https://www.pharmaradar360.com/article/marius-pharmaceuticals-backs-fda-proposal-to-revise-testosterone-therapy-warning-9a1faac6b70d19dcPharma Surgeen2026-06-24T21:11:29.000ZMarius Pharmaceuticals backs FDA proposal to revise testosterone therapy warningshttps://www.pharmaradar360.com/article/results-that-matter-co-creating-individual-study-data-reports-with-patients-45777d14f77c8058Pharma Surgeen2026-06-24T21:03:19.000ZResults that Matter: Co-Creating Individual Study Data Reports With Patientshttps://www.pharmaradar360.com/article/news-australian-firm-lends-boost-to-boston-biotech-market-with-hq-deal-3d2c5ac026dc89b2Pharma Surgeen2026-06-24T21:01:17.000ZNews | Australian firm lends boost to Boston biotech market with HQ dealhttps://www.pharmaradar360.com/article/hlb-rallies-as-korea-bets-on-fda-liver-cancer-decision-amid-cmc-risks-chosunbiz-c302826edb6d075cPharma Surgeen2026-06-24T21:01:00.000ZHLB rallies as Korea bets on FDA liver cancer decision amid CMC risks - CHOSUNBIZhttps://www.pharmaradar360.com/article/at-asms-2026-mass-spectrometry-stakes-its-claim-2b489495663fd000Pharma Surgeen2026-06-24T20:59:42.000ZAt ASMS 2026, mass spectrometry stakes its claimhttps://www.pharmaradar360.com/article/firm-advises-underwriters-on-legend-biotech-s-public-offering-6d10c7778755f32dPharma Surgeen2026-06-24T20:58:37.000ZFirm Advises Underwriters on Legend Biotech’s Public Offeringhttps://www.pharmaradar360.com/article/signs-of-recovery-in-the-biotech-industry-5547b5ca8f18525dPharma Surgeen2026-06-24T20:54:06.000ZSigns of Recovery in the Biotech Industryhttps://www.pharmaradar360.com/article/eli-lilly-and-abbisko-announce-drug-development-collaboration-pharmexec-7c713892bd147513Pharma Surgeen2026-06-24T20:38:10.000ZEli Lilly and Abbisko Announce Drug Development Collaboration | PharmExechttps://www.pharmaradar360.com/article/exozymes-awarded-2-million-nih-grant-to-advance-cannabinoid-analogs-for-drug-dis-1fbdcf63099fbf16Pharma Surgeen2026-06-24T20:07:19.000ZeXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discoveryhttps://www.pharmaradar360.com/article/hhs-proposes-clinical-trial-reform-to-catch-chinese-biotech-sector-0a23b6428df3b1afPharma Surgeen2026-06-24T19:55:59.000ZHHS Proposes Clinical Trial Reform To Catch Chinese Biotech Sectorhttps://www.pharmaradar360.com/article/bio-2026-ceo-calls-for-u-s-biotech-urgency-and-international-competitiveness-f8f871d4e91f3b22Pharma Surgeen2026-06-24T19:53:38.000ZBIO 2026: CEO Calls for U.S. Biotech Urgency and International Competitivenesshttps://www.pharmaradar360.com/article/restaurant-menus-must-have-calorie-allergen-info-maharashtra-fda-8c04f4606deb1afdPharma Surgeen2026-06-24T19:11:00.000ZRestaurant menus must have calorie & allergen info: Maharashtra FDAhttps://www.pharmaradar360.com/article/fda-must-reinstate-safety-restrictions-for-abortion-drug-9864f068ae0dd0b6Pharma Surgeen2026-06-24T18:57:15.000ZFDA Must Reinstate Safety Restrictions for Abortion Drughttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-partnerships-facilitating-antibody-discovery-and-ai-drug-d-28f4155f5ab104fcPharma Surgeen2026-06-24T18:29:35.000ZThe biotech bi-weekly: partnerships facilitating antibody discovery and AI drug developmenthttps://www.pharmaradar360.com/article/restaurant-license-suspended-cheese-analogue-sold-as-paneer-pune-fda-launches-cr-9076a6ca598acca5Pharma Surgeen2026-06-24T18:23:21.000ZRestaurant license suspended | Cheese analogue sold as paneer: Pune FDA launches crackdownhttps://www.pharmaradar360.com/article/how-a-drug-with-more-negative-than-positive-studies-won-fda-approval-f5e95544772a9b9bPharma Surgeen2026-06-24T18:01:38.000ZHow a Drug With More Negative Than Positive Studies Won FDA Approvalhttps://www.pharmaradar360.com/article/yellow-fever-global-f31c497d0f687d00Pharma Surgeen2026-06-24T18:00:00.000ZYellow fever - Globalhttps://www.pharmaradar360.com/article/lly-stock-down-as-fda-asks-for-more-safety-data-on-oral-obesity-pill-e002c6564c96427bPharma Surgeen2026-06-24T17:53:51.000ZLLY stock down as FDA asks for more safety data on oral obesity pillhttps://www.pharmaradar360.com/article/chemical-explosion-fire-reported-at-rockland-county-pharmaceutical-facility-9ff29e52add97bbdPharma Surgeen2026-06-24T17:45:00.000ZChemical explosion, fire reported at Rockland County pharmaceutical facilityhttps://www.pharmaradar360.com/article/sellas-life-sciences-group-sls-looks-pricey-following-phase-3-regal-trial-progre-cdd7e2376de24469Pharma Surgeen2026-06-24T17:40:41.000ZSELLAS Life Sciences Group (SLS) Looks Pricey Following Phase 3 REGAL Trial Progresshttps://www.pharmaradar360.com/article/interfarma-apresenta-estudo-sobre-avancos-da-pesquisa-clinica-no-brasil-pais-gan-98ce2026b553088ePharma Surgeen2026-06-24T17:38:02.000ZInterfarma apresenta estudo sobre avanços da pesquisa clinica no Brasil: país ganha posições importanteshttps://www.pharmaradar360.com/article/fda-approves-palbociclib-for-hr-her2-metastatic-breast-cancer-maintenance-1ab14dbd645932efPharma Surgeen2026-06-24T17:01:39.000ZFDA Approves Palbociclib for HR+/HER2+ Metastatic Breast Cancer Maintenancehttps://www.pharmaradar360.com/article/pfizer-advances-new-pediatric-pneumococcal-catch-up-vaccine-in-phase-3-trial-9cc6353448e2ee5aPharma Surgeen2026-06-24T16:50:23.000ZPfizer Advances New Pediatric Pneumococcal “Catch-Up” Vaccine in Phase 3 Trialhttps://www.pharmaradar360.com/article/from-unexpected-turns-to-purposeful-impact-0b7bdbe935bcb0f0Pharma Surgeen2026-06-24T16:43:00.000ZFrom Unexpected Turns to Purposeful Impacthttps://www.pharmaradar360.com/article/explosion-happens-in-pharmaceutical-building-in-rockland-county-4b0dec375c4e7d88Pharma Surgeen2026-06-24T16:30:00.000ZExplosion happens in pharmaceutical building in Rockland Countyhttps://www.pharmaradar360.com/article/moulton-pledges-investments-in-biotech-affordable-housing-8a655ce5cb03bed5Pharma Surgeen2026-06-24T16:25:11.000ZMoulton pledges investments in biotech, affordable housinghttps://www.pharmaradar360.com/article/mycobacterium-chimaera-infections-linked-to-heater-cooler-units-60a23db6445013c2Pharma Surgeen2026-06-24T16:21:02.000ZMycobacterium chimaera: infections linked to heater cooler unitshttps://www.pharmaradar360.com/article/foreign-secretary-announces-support-for-gaza-with-new-child-medical-evacuations-e6dcf7853d8be341Pharma Surgeen2026-06-24T15:48:52.000ZForeign Secretary announces support for Gaza with new child medical evacuations and assistance to Palestinians going to top UK universitieshttps://www.pharmaradar360.com/article/semaglutide-surge-associated-with-spike-in-poison-control-calls-9281278bc843d0b5Pharma Surgeen2026-06-24T15:48:47.000ZSemaglutide Surge Associated With Spike in Poison Control Callshttps://www.pharmaradar360.com/article/a-dispatch-on-ai-from-biotech-s-big-summer-bash-cb3d3b73dd6c4f90Pharma Surgeen2026-06-24T15:45:11.000ZA dispatch on AI from BIOtech’s big summer bashhttps://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-d0cb2f53bbf31f42Pharma Surgeen2026-06-24T15:30:09.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/fda-complete-response-letter-crl-explained-what-it-means-for-biotech-stocks-7427cea75a999a61Pharma Surgeen2026-06-24T15:12:00.000ZFDA Complete Response Letter (CRL) Explained: What It Means For Biotech Stockshttps://www.pharmaradar360.com/article/general-medical-services-statement-of-financial-entitlements-directions-4a85d169127d6c46Pharma Surgeen2026-06-24T15:10:36.000ZGeneral Medical Services Statement of Financial Entitlements Directionshttps://www.pharmaradar360.com/article/physician-views-preview-sanofi-secures-european-approval-for-tolebrutinib-in-und-77eab8584c5238afPharma Surgeen2026-06-24T15:09:34.000ZPhysician Views Preview: Sanofi secures European approval for tolebrutinib in underserved MS populationhttps://www.pharmaradar360.com/article/what-parents-should-know-about-generic-drugs-308c8b4c7a5c7305Pharma Surgeen2026-06-24T15:02:45.000ZWhat Parents Should Know About Generic Drugshttps://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2Pharma Surgeen2026-06-24T14:51:32.000ZUKHSA spend over £25,000: 2026https://www.pharmaradar360.com/article/ukhsa-extends-red-heat-health-alerts-across-england-3ab1f8a5ec9bfc1dPharma Surgeen2026-06-24T14:47:03.000ZUKHSA extends red heat-health alerts across Englandhttps://www.pharmaradar360.com/article/haisco-and-nuvectis-sign-licensing-deal-for-two-drugs-a741fb23593958b6Pharma Surgeen2026-06-24T14:31:07.000ZHaisco and Nuvectis sign licensing deal for two drugshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-hits-52-week-high-at-338-73-61b58ce637bf150dPharma Surgeen2026-06-24T14:20:19.000ZWest Pharmaceutical Services stock hits 52-week high at $338.73https://www.pharmaradar360.com/article/news-pharmaceutical-giant-plans-more-than-1-billion-expansion-in-jacksonville-fl-b6b5ca31dd14d7b6Pharma Surgeen2026-06-24T14:19:51.000ZNews | Pharmaceutical giant plans more than $1 billion expansion in Jacksonville, Floridahttps://www.pharmaradar360.com/article/at-bio-a-glimpse-behind-lilly-and-chai-s-partnership-cef7fd9e504fd687Pharma Surgeen2026-06-24T14:14:53.000ZAt BIO, a glimpse behind Lilly and Chai’s partnershiphttps://www.pharmaradar360.com/article/drug-discovery-technologies-market-2026-2030-in-f8be93385467bd32Pharma Surgeen2026-06-24T14:09:42.000ZDrug Discovery Technologies Market 2026-2030 | In